M Bijmolen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND In the era of highly effective direct-acting antivirals (DAAs) for treatment of patients with chronic hepatitis C virus (HCV) infection, ribavirin (RBV) is still considered beneficial in certain patients. AIM To assess the association between RBV steady-state plasma levels and sustained virological response (SVR). METHODS Consecutive(More)
  • 1